Antibody Engineering

Antibody Engineering encompasses molecular modification techniques altering antibody structure to improve therapeutic properties including affinity, selectivity, stability, half-life, and effector functions, or enabling novel multispecific formats. These approaches employ rational design, directed evolution, computational modelling, and high-throughput screening identifying optimal antibody variants.

The biopharmaceutical industry has transformed therapeutic antibody capabilities through engineering advances. Fc engineering modifies constant regions altering immune effector recruitment, complement activation, or FcRn binding affecting half-life. CDR optimisation through affinity maturation improves binding potency. Humanisation reduces immunogenicity replacing non-human framework sequences. Bispecific formats enable dual targeting. Antibody-drug conjugate design optimises attachment sites, drug-to-antibody ratios, and payload chemistry. As computational design capabilities advance and structural biology provides atomic-level insights, antibody engineering continues creating increasingly sophisticated molecules addressing previously intractable therapeutic challenges across diverse disease areas.